What is Stereotaxis, Inc. (STXS) stock price today?

Stereotaxis, Inc. (STXS) is currently trading at $1.11, up 0% today.

What is STXS P/E ratio?

Stereotaxis, Inc.'s P/E ratio is -4.78. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is STXS return on equity (ROE)?

Stereotaxis, Inc.'s return on equity (ROE) is -132.62%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Stereotaxis, Inc.'s market cap?

Stereotaxis, Inc. has a market capitalization of $108.71M.

AMEX · Medical - Instruments & Supplies

Stereotaxis, Inc. (STXS) Stock

$1.11 +0.00% AMEX: STXS Healthcare

Valuation

Metric	Value
Price	$1.11
Market Cap	$108.71M
P/E Ratio	-4.78
P/B Ratio	6.75
P/S Ratio	3.84
EPS (TTM)	$-0.25
52-Week High	$3.59
52-Week Low	$1.10
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-132.62%
ROA	-40.16%
ROCE	-76.27%
Gross Margin	-68.75%
Operating Margin	-68.75%
Net Margin	-74.24%
Debt/Equity	0.30
Current Ratio	1.55

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$35.0M	$28.0M	$27.0M	$27.0M	$32.0M
Operating Profit	$-13.0M	$-19.0M	$-22.0M	$-25.0M	$-22.0M
Net Profit	$-11.0M	$-18.0M	$-21.0M	$-24.0M	$-22.0M
EPS	$-0.16	$-0.26	$-0.27	$-0.30	$-0.25
Op Margin	-36.8%	-66.7%	-81.6%	-91.9%	-68.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$61.0M	$53.0M	$42.0M	$47.0M	$52.0M
Total Liabilities	$22.0M	$21.0M	$20.0M	$35.0M	$34.0M
Cash	$39.0M	$9.0M	$20.0M	$12.0M	$13.0M
Borrowings	$6.0M	$6.0M	$5.0M	$6.0M	$5.0M

Latest News

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026 GlobeNewswire · Jul 21, 2026 University of Szeged Pioneers First Robotic Cardiology Program in Hungary GlobeNewswire · Jul 20, 2026 Stereotaxis (STXS) Could Be 56% Undervalued After Shelf Registration Filings Simply Wall St. · Jul 20, 2026 Stereotaxis Files Resale Registration for Up to 108.9 Million Shares MT Newswires · Jul 15, 2026 Can ISRG Defend Its Leadership as Global Competition Intensifies? Zacks · Jul 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-3.0M	$-8.0M	$-9.0M	$-8.0M	$-14.0M
Investing Cash Flow	$-3.0M	$-24.0M	$19.0M	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-4.0M	$-30.0M	$11.0M	$-8.0M	$1.0M
Free Cash Flow	$-4.0M	$-11.0M	$-10.0M	$-9.0M	$-14.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.46
EV / EBITDA	-5.22
FCF Yield	-13.42%
Quick Ratio	0.95
Interest Coverage	0.00
Return 1Y	-29.52%
Return 3Y	7.38%
Return 5Y	-82.42%

Ownership

Insiders Held15.29%

Institutions Held44.00%

Institutions Float Held51.94%

Institutional Holder	Shares	Report Date
DAFNA Capital Management, LLC	13,680,554	2026-03-31
Lagoda Investment Management, L.P.	4,350,400	2026-03-31
Blackrock Inc.	3,956,243	2026-03-31
Vanguard Capital Management LLC	2,998,044	2026-03-31
Arbiter Partners Capital Management LLC	2,883,856	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CLPTClearPoint Neuro Inc.	$10.48	-0.10%	-12.57	$314.29M	0.00%
MBOTMicrobot Medical Inc.	$1.07	+0.00%	-4.45	$48.76M	0.00%
NPCENeuropace, Inc.	$12.67	+2.26%	-22.21	$431.97M	0.00%
SSIISS Innovations International Inc.	$2.65	+0.57%	-40.95	$529.35M	0.00%
VJETFlyte Aviation, Inc.	$1.14	+13.43%	-0.37	$239627	0.00%

About Stereotaxis, Inc.

Stereotaxis, Inc. is led by CEO David Leo Fischel, employs 139 people, headquartered in US, publicly traded since 2004.

Stereotaxis, Inc. (STXS) stock trades at $1.11 with a market capitalization of $108.71M. The stock is valued at a price-to-earnings (P/E) ratio of -4.78, price-to-book of 6.75, price-to-sales of 3.84. Over the past 52 weeks the stock has ranged between $1.10 and $3.59, and currently trades 69.1% below its 52-week high.

On profitability, Stereotaxis, Inc. generates a return on equity (ROE) of -132.62%, return on capital employed of -76.27%, an operating margin of -68.75%, a net profit margin of -74.24%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides